Macrolide Antibiotics Global Market Report 2024

Macrolide antibiotics are characterized by a macrocyclic lactone ring to which one or more sugars are attached. They exert their antibacterial effect by binding to the 50S ribosomal subunit, thereby inhibiting bacterial protein synthesis. This mechanism makes them effective against a wide range of Gram-positive bacteria and some Gram-negative bacteria.

Azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin are the main types of macrolide antibiotics. Azithromycin, for instance, inhibits bacterial growth by disrupting protein synthesis. It is used to treat respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, among others. Azithromycin can be administered orally, parenterally, or through other routes. It is distributed through hospital pharmacies, retail drug stores, and online providers, and is utilized by various end users such as hospitals, dermatology clinics, outpatient clinics, ambulatory centers, and research laboratories.

The macrolide antibiotics market research report is one of a series of new reports that provides macrolide antibiotics market statistics, including macrolide antibiotics industry global market size, regional shares, competitors with a macrolide antibiotics market share, detailed macrolide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the macrolide antibiotics industry. This macrolide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macrolide antibiotics market size has grown rapidly in recent years. It will grow from $52.98 billion in 2023 to $59.07 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth observed in the historical period can be credited to factors such as increasing antibiotic resistance, approvals for new formulations, a rise in infectious diseases, and initiatives from governments and healthcare sectors.

The macrolide antibiotics market size is expected to see rapid growth in the next few years. It will grow to $91.64 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The forecast period growth is anticipated due to an increase in respiratory infections driven by factors such as a rise in combination therapies, a growing global geriatric population, heightened awareness and diagnostics, and the expansion of telemedicine and online pharmacy services. Key trends expected in the forecast period include advancements in drug delivery systems and formulations, the development of novel macrolide antibiotics, progress in telemedicine and remote healthcare services, and the adoption of eco-friendly manufacturing processes for macrolide antibiotics.

The growth of the macrolide antibiotics market is expected to be driven by the increasing prevalence of skin infections in the coming years. Skin infections occur when harmful microorganisms invade the skin, causing inflammation and often accompanied by symptoms such as redness, swelling, and pain. Factors contributing to the rise in skin infections include poor hygiene practices, compromised immune systems, exposure to environmental pollutants, antibiotic resistance, and inadequate wound care. Macrolide antibiotics are commonly prescribed to treat skin infections caused by bacteria such as Staphylococcus aureus or Streptococcus pyogenes, especially in cases of penicillin allergy or resistance. For example, according to the UK Health Security Agency (UKHSA) in September 2022, the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases attributed to skin and soft tissue infections increased from 25.7% to 33.7% between April 2020 to March 2021 and April 2021 to March 2022. Similarly, for Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia cases, the percentage rose from 27.2% to 28.5% over the same period, indicating a rising trend in skin infections driving the macrolide antibiotics market.

Key players in the macrolide antibiotic market are focusing on developing generic formulations to enhance accessibility, reduce treatment costs, and broaden their market presence. Generic formulations are unbranded versions of these drugs containing the same active ingredients, dosage, and strength as the original branded medications. For instance, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched its generic version of Erythromycin Tablets USP in May 2021 in the United States. This generic medication is used to treat or prevent various bacterial infections, including respiratory tract infections, skin infections, and infections of the ear, nose, and throat. Erythromycin, a macrolide antibiotic, works by inhibiting bacterial growth, thus alleviating symptoms and preventing infection spread. The generic Erythromycin Tablets USP is available in strengths such as 250 mg and 500 mg, offering patients a more affordable treatment option for bacterial infections.

In April 2024, Aztiq, an Iceland-based long-term investment fund, acquired Alvogen Emerging Markets Holdings Limited from PTT Public Company Limited for an undisclosed sum. The acquisition aims to accelerate Adalvo's growth and expansion by leveraging the combined strengths of Aztiq and Innobic (Asia), PTT's wholly-owned Life Science arm. Adalvo, a US-based pharmaceutical company, specializes in providing macrolide antibiotics.

Major companies operating in the macrolide antibiotics market are Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyō, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited.

North America was the largest region in the macrolide antibiotics market in 2023. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the macrolide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macrolide antibiotics market consists of sales of oral tablets and capsules such as dirithromycin, josamycin, spiramycin, and roxithromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.